Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Iovance Biotherapeutics Earnings Call: Key Takeaways

Iovance delivered record Q3 revenue of $122 million and 60% margins, driven by strong Amtagvi adoption and a cash runway extended into 2029.

Why this was an Alfa AlertManagement guides 60% Revenue growth for 2026 (explicit single-year guidance).
Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue $122M, up 80% YoY; Amtagvi $102M; Proleukin $20M.
Mgmt ConfidenceHigh confidence in achieving 2026 goals and reaching profitability via growth.
Demand VisibilityOver 1,000 commercial patients treated; 100+ Authorized Treatment Centers active.
Margin TrendsRecord 60% margin in Q3, up from 56% in Q2.
Op. LeverageR&D expenses down 16% sequentially; SG&A held flat despite revenue growth.
Pricing PowerHigh-quality revenue with gross-to-net deductions consistent at approximately 1%.
Vol vs PriceVolume-led growth through increased patient infusions and expanded ATC network.
Segment GrowthAmtagvi sales grew 77% YoY; Proleukin revenue more than doubled sequentially.
New ClientsAdded community-based ATCs, now representing over one-third of the network.
Capex & DebtCash position of $382M expected to fund operations into 2029.
RegulatoryPlanned 2027 sBLA for lung cancer; Saratoga trial supporting 2028/2029 submissions.
CommentaryFocusing on 'precision TIL' strategy using biomarkers to reach 59.1% ORR.
New LaunchesExpanding into Canada and Australia; UK and Swiss approvals expected Q1 2027.

Growth

Total revenue grew 80% year-over-year; Amtagvi sales reached $102 million, up 12% sequentially.

Outlook

Reaffirmed 2026 revenue guidance of $410M-$420M; planning lung cancer sBLA submission in 2027.

Risks

Management provided vague timing on mature lung cancer durability data and future profitability milestones.

Source

The company's earnings call, NASDAQ: IOVA, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Iovance Biotherapeutics, Inc.: key numbers

Share price
$7.55Close, Nov 16
Market cap
$3.49B
Shares outstanding
462.66MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Iovance Biotherapeutics, Inc.

All →
5:01 PM ET 8-K
Investor Presentation

Iovance Biotherapeutics Investor Presentation

Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The November 2026 presentation provides a corporate overview and updates on the company's cell therapy pipeline and commercialization efforts.

9:16 AM ET 10-Q
Financial Results ▶ Call

Iovance Biotherapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Narrows

Iovance Biotherapeutics reported significant revenue growth for the nine months ended September 30, 2026, reaching $292.2 million compared to $176.7 million in the prior year. The company successfully narrowed its net loss to $148.6 million from $319.1 million, supported by reduced research and development expenses and increased product sales.

Key figure
Net loss $22.3M
7:09 AM ET 8-K
Financial Results

Iovance Biotherapeutics Financial Results

Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.

Term
Q3 2026

“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”

Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
5:01 PM ET 8-K
Clinical Trial Data

Iovance Biotherapeutics Clinical Trial Data

Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.

5:01 PM ET 8-K
Investor Presentation

Iovance Biotherapeutics Investor Presentation

Iovance Biotherapeutics updated its corporate presentation for use at upcoming healthcare conferences and meetings with analysts and stockholders. The presentation provides a corporate overview and strategic update as of October 2026.

7:06 AM ET 8-K
Investor Meeting

Iovance Biotherapeutics Investor Meeting

Iovance Biotherapeutics raised its full-year 2026 total revenue guidance to a range of $410 million to $420 million, up from the previous range of $350 million to $370 million. The increase is driven by strong U.S. demand for its cancer therapies Amtagvi and Proleukin, representing approximately 60% annual growth.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.